Side-by-side comparison of AI visibility scores, market position, and capabilities
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
SF YC W23 multimodal AI agents for game testing and playing without source code access; $8M total ($6M TIRTA/a16z/YC seed Mar 2025) with vision-based interaction competing with Modl.ai for automated game QA.
nunu.ai is a San Francisco-based AI game testing and playing platform — backed by Y Combinator (W23) with $8 million in total funding including a $6 million seed in March 2025 led by TIRTA with Andreessen Horowitz (a16z GAMES), Y Combinator, FOV Ventures, Factorial Funds, Earthling VC, Hartmann Capital, and New Renaissance Ventures, following a $2 million pre-seed in 2024 from a16z GAMES, SPEEDRUN, and Y Combinator — providing game developers and studios with multimodal AI agents that can see and interact with any game like a human player, enabling automated game testing, QA, and gameplay analysis across any game without custom integration. Founded in 2022 by Kyrill Hux, Nicolas Muntwyler, and Jan Schnyder, nunu.ai operates with 5 employees targeting both game testing automation and broader gaming AI agent applications.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.